Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Engene Holdings Inc (ENGN)

Engene Holdings Inc (ENGN)
3.90 x 1 6.29 x 2
Post-market by (Cboe BZX)
4.00 +0.01 (+0.25%) 04/22/25 [NASDAQ]
3.90 x 1 6.29 x 2
Post-market 4.00 unch (unch) 16:00 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.90
Day High
4.19
Open 4.00
Previous Close 3.99 3.99
Volume 82,047 82,047
Avg Vol 46,082 46,082
Stochastic %K 38.21% 38.21%
Weighted Alpha -68.32 -68.32
5-Day Change unch (unch) unch (unch)
52-Week Range 3.50 - 16.62 3.50 - 16.62
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 203,398
  • Shares Outstanding, K 50,977
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,140 K
  • EBIT $ -78 M
  • EBITDA $ -78 M
  • 60-Month Beta -0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/25
See More
  • Average Estimate -0.50
  • Number of Estimates 6
  • High Estimate -0.32
  • Low Estimate -0.60
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.50 +14.29%
on 04/10/25
Period Open: 4.96
5.06 -20.95%
on 03/24/25
-0.96 (-19.35%)
since 03/21/25
3-Month
3.50 +14.29%
on 04/10/25
Period Open: 6.95
7.72 -48.18%
on 01/27/25
-2.95 (-42.45%)
since 01/22/25
52-Week
3.50 +14.29%
on 04/10/25
Period Open: 14.80
16.62 -75.93%
on 04/29/24
-10.80 (-72.97%)
since 04/22/24

Most Recent Stories

More News
Best Momentum Stocks to Buy for February 19th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 19:Nova Ltd. NVMI: This semiconductor equipment company has a Zacks Rank #1 and witnessed...

NVMI : 174.13 (+0.73%)
FRSH : 12.21 (+1.16%)
ENGN : 4.00 (+0.25%)
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...

ENGN : 4.00 (+0.25%)
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...

ENGN : 4.00 (+0.25%)
/C O R R E C T I O N -- enGene Inc./

In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by...

ENGN : 4.00 (+0.25%)
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...

ENGN : 4.00 (+0.25%)
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...

ENGN : 4.00 (+0.25%)
enGene To Present at the Leerink Partners Global Biopharma Conference

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...

ENGN : 4.00 (+0.25%)
enGene Announces Oversubscribed $200 Million Private Placement Financing

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...

ENGN : 4.00 (+0.25%)
enGene Announces Leadership Succession Plan

/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...

ENGN : 4.00 (+0.25%)
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

/CNW/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for...

ENGN : 4.00 (+0.25%)

Business Summary

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

See More

Key Turning Points

3rd Resistance Point 4.45
2nd Resistance Point 4.32
1st Resistance Point 4.16
Last Price 4.00
1st Support Level 3.87
2nd Support Level 3.74
3rd Support Level 3.58

See More

52-Week High 16.62
Fibonacci 61.8% 11.61
Fibonacci 50% 10.06
Fibonacci 38.2% 8.51
Last Price 4.00
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro